Key points are not available for this paper at this time.
The optimal systemic treatment for stage I TNBC remains unclear, given the lack of well-designed randomized trials. sTILs have emerged as a prognostic biomarker in early TNBC. We aimed to study the impact of (neo)adjuvant CT use and sTILs in the prognosis of pts with stage I TNBC. Pts with stage I TNBC (ER50%, which associated with higher grade and Ki67. With a median follow-up of 7.2 years (IC: 3.0 – 21.8), 19/108 (18%) had a progression event, 9 (8%) distant metastases. 5y iDFS, DDFS, and OS rates are presented in the table. (Neo)adjuvant CT was not associated with better iDFS (p=.53), DDFS (p=.66) or OS (p=.89). In multivariate analyses for the survival endpoints, no interaction was observed between sTILs (both as categorical and continuous variables) and CT use.Table: 27P5-year ratesNiDFS (%)DDFS (%)OS (%)Overall population10883.691.298.9sTILs >50%2788.7100100sTILs 50%2387100100CT and sTILs50%4100100100No CT and sTILs<50%16808793∗ p=.63.† p=.34.‡ p=.68. Open table in a new tab In this retrospective cohort, a high proportion of patients with stage I TNBC received CT, which was not associated with better outcomes, irrespectively of the abundance of sTILs. The role of (neo)adjuvant CT in stage I TNBC should be studied in prospective trials to identify patients that can be spared systemic treatment.
Barberi et al. (Wed,) studied this question.